Chardan Capital reissued their buy rating on shares of Zura Bio (NASDAQ:ZURA – Free Report) in a research report report published on Tuesday,Benzinga reports. Get Zura Bio alerts:Check Out Our Latest Stock Analysis on ZURAZura Bio Trading Up 1.5%NASDAQ ZURA opened at $4.10 on Tuesday. Zura Bio (NASDAQ:ZURA – Get Free Report) last issued its quarterly earnings data on Thursday, August 14th. Zura Bio Company Profile(Get Free Report)Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. See AlsoReceive News & Ratings for Zura Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zura Bio and related companies with MarketBeat.com's FREE daily email newsletter.